ATLANTA, Nov. 1, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc., an Atlanta, GA-based biopharmaceutical company focused on new treatment options to better manage central nervous system diseases, announced today that it has been chosen as one of only 12 companies selected in the competition for a "main-stage" presentation at the Ninth Annual Southeastern BIO Investor Forum (SEBIO) to be held November 7-8, 2007, in Pinehurst, N.C. Dr. Harold H. Shlevin, president and chief executive officer of Tikvah Therapeutics, Inc., will present a corporate overview on Thursday, November 8, 2007, at 11:15 am EST.
"We are honored to have been selected by SEBIO for the main-stage presentation and look forward to the opportunity to discuss our therapeutic pipeline with those in attendance," said Dr. Harold Shlevin.
The Southeastern BIO Investor Forum is the region's premier life science venture capital conference, connecting emerging life science companies with potential investors in a forum that provides networking opportunities. The conference attracts over 400 attendees, including investors from the Southeast and from around the world, SEBIO showcases emerging life sciences companies from Alabama, Florida, Georgia, North Carolina, South Carolina, Virginia and beyond each year. This year, of the over 60 life sciences companies applying to present at SEBIO, just 12 were selected as "main-stage" presenting companies and 12 were selected for the "Early-Stage Shootout" contest.
About Tikvah Therapeutics, Inc.
Atlanta-based Tikvah Therapeutics, Inc. focuses on exploring new uses for late-stage pharmaceutical compounds in selected therapeutic indications of central nervous system diseases, including neurology and psychiatry disorders. Its focus is on new therapeutic uses which have been confirmed in multiple, clinical proof-of-concept studies. This strategy aims to shorten product development timelines and substantially decreases the risk associated with the research and development efforts. A second prong of its strategy is to focus on specialized products with multiple stepping-stone indications and strong patent protections, thus helping to ensure long product life cycles and manageable commercial risk. For further information, please see www.tikvahtherapeutics.com
"TIKVAH THERAPEUTICS, INC.," "Bringing Hope to Life," and the above logo design are trademarks of Tikvah Therapeutics, Inc., Atlanta, Georgia USA